Azathioprine Hypersensitivity Syndrome during Treatment of Severe Interstitial Lung Disease with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Table 1
Laboratory findings during the course of the disease.
At diagnosis
⓪
①
②
③
④
2 years after MMF therapy
Units
WBC
12,570
10,990
10,840
10,100
19,650
16,410
6,030
/μL
Hb
12.2
12.1
12.1
12.3
14
11.8
10.4
mg/dL
Plt
43.7
35.8
32.8
19.4
52.6
26.7
34.0
104/μL
Alb
2.5
3.1
3.1
3.0
2.4
3.8
mg/dL
LDH
209
264
232
300
244
334
206
IU/L
AST
29
18
36
24
35
50
22
IU/L
ALT
37
15
30
26
28
39
10
IU/L
CPK
54
19
17
38
20
38
43
IU/L
BUN
20.9
26.1
28.5
20.8
34.1
70.4
18.2
mg/dL
Cr
0.93
1.40
1.55
1.30
1.66
6.34
1.24
mg/dL
Na
137
140
138
139
137
136
141
mEq/L
K
4.6
4.6
5.5
4.2
4.3
4.9
4.0
mEq/L
Cl
104
104
102
103
101
103
100
mEq/L
CRP
19.92
2.22
9.23
10.87
16.19
31.19
0.43
mg/dL
Urine protein
2+
−
−
2+
±
2+
−
Urine occult blood
3+
3+
3+
3+
3+
3+
2+
Urine sediment (RBC)
50-99
50-99
50-99
>100
>100
>100
50-99
/HPF
β-D-Glucan
9.6
11.9
7.7
pg/mL
CMV-antigenemia
neg.
neg.
neg.
SP-D
<17.2
23.7
mg/dL
KL-6
1,220
469
U/mL
IgG
731
583
mg/dL
Anti-MPO-ANCA
>300
>300
>300
>300
>300
U/mL
Anti-GBM-Ab
<2.0
<2.0
U/mL
Anti-PR3-ANCA
<1.0
U/mL
Anti-nuclear antibody
×40
ANCA: anti-neutrophil cytoplasmic antibodies; CMV: cytomegalovirus; GBM: glomerular basement membrane; KL-6: Krebs von den Lungen-6; MMF: mycophenolate mofetil; MPO: myeloperoxidase; PR3: proteinase 3; SP-D: surfactant protein d; RBC: red blood cell.
